Yes it is IMO $10 mil for a 200 person Phase 3, and if necessary a direct multiple to $20 mil for 400 persons etc. Notice also that ICT is also showing 2 years from 2018 to 2020 duration for their clinical trial. Yes still chump change for a Multi-$Bil BP.
Vericel brings 20 years of Ixcell DCM research to the table. What a gift indeed to Partner with for any forward thinking BP that understands Biotechs are our ultimate therapies and that $VCEL P2B is a smashing success.
As well the big advantage of an Asian partner is that a FDA USA trial immediately leads to direct Commercial approval in their own country. China has a declining population of 1.2 bil people that are aging due to mandated birth control and there is a big need to treat their professional aging scientists, inventors, doctors etc
News 
Market Data 
Discover 
